2 Growth Stocks to Stash and 1 to Question
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle.
One-Year Revenue Growth: +25.3%
Founded in 2009 by enterprise software veteran Tom Seibel, C3.ai (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications.
Why Does AI Fall Short?
15.5% annual revenue growth over the last three years was slower than its software peers
Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions
Historical operating margin losses point to an inefficient cost structure
C3.ai's stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI.
One-Year Revenue Growth: +32.3%
Founded in 2014 and named after the dreaded first day of the work week, Monday.com (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently.
Why Is MNDY a Good Business?
ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability
Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5%
Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently
Monday.com is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free.
One-Year Revenue Growth: +20%
Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals.
Why Should DOCS Be on Your Watchlist?
Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time
Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale
DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free.
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
MetLife (MET) To Report Earnings Tomorrow: Here Is What To Expect
Global insurance giant MetLife (NYSE:MET) will be reporting results this Wednesday afternoon. Here's what investors should know. MetLife beat analysts' revenue expectations by 3% last quarter, reporting revenues of $18.83 billion, up 10.6% year on year. It was a slower quarter for the company, with a significant miss of analysts' book value per share estimates and a miss of analysts' EPS estimates. Is MetLife a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting MetLife's revenue to be flat year on year at $18.64 billion, in line with its flat revenue from the same quarter last year. Adjusted earnings are expected to come in at $2.16 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. MetLife has missed Wall Street's revenue estimates four times over the last two years. Looking at MetLife's peers in the life insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corebridge Financial delivered year-on-year revenue growth of 5.8%, beating analysts' expectations by 7.3%, and Lincoln Financial Group reported revenues up 4.4%, topping estimates by 1.1%. Lincoln Financial Group traded up 7.8% following the results. Read our full analysis of Corebridge Financial's results here and Lincoln Financial Group's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the life insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. MetLife is down 5.3% during the same time and is heading into earnings with an average analyst price target of $94.14 (compared to the current share price of $75). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
3 minutes ago
- Yahoo
HubSpot (HUBS) Reports Q2: Everything You Need To Know Ahead Of Earnings
Sales and marketing software maker HubSpot (NYSE:HUBS) will be announcing earnings results this Wednesday afternoon. Here's what to look for. HubSpot beat analysts' revenue expectations by 2% last quarter, reporting revenues of $714.1 million, up 15.7% year on year. It was a strong quarter for the company, with an impressive beat of analysts' billings estimates and a solid beat of analysts' EBITDA estimates. It added 10,319 customers to reach a total of 258,258. Is HubSpot a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting HubSpot's revenue to grow 16% year on year to $739.3 million, slowing from the 20.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. HubSpot has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 3.1% on average. Looking at HubSpot's peers in the sales and marketing software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Freshworks delivered year-on-year revenue growth of 17.5%, beating analysts' expectations by 2.9%, and BigCommerce reported revenues up 3.2%, topping estimates by 1.3%. Freshworks traded down 2.5% following the results while BigCommerce was up 4.6%. Read our full analysis of Freshworks's results here and BigCommerce's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the sales and marketing software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3% on average over the last month. HubSpot is down 7.8% during the same time and is heading into earnings with an average analyst price target of $736.74 (compared to the current share price of $512.20). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Primerica Earnings: What To Look For From PRI
Financial services company Primerica (NYSE:PRI) will be reporting results this Wednesday after market hours. Here's what to expect. Primerica beat analysts' revenue expectations by 2.1% last quarter, reporting revenues of $803.6 million, up 9.4% year on year. It was a mixed quarter for the company, with net premiums earned in line with analysts' estimates but a slight miss of analysts' book value per share estimates. Is Primerica a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Primerica's revenue to grow 6.1% year on year to $786.1 million, slowing from the 9.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.20 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Primerica has missed Wall Street's revenue estimates four times over the last two years. Looking at Primerica's peers in the life insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corebridge Financial delivered year-on-year revenue growth of 5.8%, beating analysts' expectations by 7.3%, and Lincoln Financial Group reported revenues up 4.4%, topping estimates by 1.1%. Lincoln Financial Group traded up 7.8% following the results. Read our full analysis of Corebridge Financial's results here and Lincoln Financial Group's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the life insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. Primerica is down 2.8% during the same time and is heading into earnings with an average analyst price target of $307.29 (compared to the current share price of $265.39). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
